How Targeted Therapy Is Given: Daily Tablets, Infusions and the Routine Between Visits

The pharmacy bag sits on the kitchen counter next to the cereal. Inside is a small bottle, a folded leaflet, and a treatment for cancer. For many people, this is the moment the question becomes real: how is targeted therapy given, and what does a treatment that lives in a kitchen cupboard actually ask of you?

For others, the first day looks entirely different. It starts with a reclining chair, a warm blanket, a nurse checking a wristband, and a slow drip through a line in the arm. Same category of medicine, same word on the referral letter, completely different rhythm.

That gap is not a sign that one route is more serious than the other. It reflects chemistry, biology and the practical judgment of a care team. This explainer walks through what the routes involve, what the weeks in between usually contain, and which questions are worth asking before you leave the clinic.

How is targeted therapy given? The short answer in plain terms

Targeted therapy is a group of cancer medicines designed to act on specific molecules that cancer cells depend on to grow, divide or spread. That definition matters for the question of delivery, because the route a medicine takes into the body is dictated largely by what kind of molecule it is.

Broadly, there are two chemical families. Small-molecule drugs are compounds tiny enough to slip inside cells and survive the acid of the stomach, so most of them are swallowed as tablets or capsules. Monoclonal antibodies are large laboratory-made proteins that would be digested like any other protein if eaten, so they are given by infusion into a vein or, for some newer formulations, by injection under the skin. The National Cancer Institute describes both families and notes that small molecules are usually oral while antibodies are usually given intravenously.

Within those two families, the schedule varies widely:

• Oral medicines are typically taken every day, sometimes with planned breaks built into a cycle.
• Infused medicines are typically spaced days or weeks apart, because antibodies remain active in the bloodstream far longer than most swallowed drugs.
• Some regimens combine a daily tablet with a periodic infusion, or pair a targeted medicine with chemotherapy or hormone therapy.

A cycle, a word you will hear often, is simply a repeating block of treatment and rest that the team uses to plan and track progress.

The practical upshot is that two people in the same waiting room can both be “on targeted therapy” and live very different weeks. One organizes life around a pillbox. The other organizes it around a calendar of appointments. Both will also have a third element that is easy to overlook when the focus is on the medicine itself: the monitoring routine between visits, which is where much of the real work of this treatment happens.

How targeted therapy works inside the body, and why that shapes the schedule

Picture a cancer cell as a factory running on a faulty signal. A gene change has left a growth switch stuck in the “on” position, so the cell keeps dividing when it should pause. Targeted medicines are built to interfere with that specific switch rather than with all rapidly dividing cells in the body.

A kinase is an enzyme, a protein that passes chemical messages along a chain inside the cell. Many oral targeted medicines are kinase inhibitors: they sit in the enzyme’s active pocket and block the message. Because the block is only maintained while the drug is present, and because most small molecules are cleared from the blood within hours, these medicines are usually taken every day. Skipping days lets the signal resume. That is the pharmacological reason daily tablets are daily, not an arbitrary rule.

Monoclonal antibodies work from the outside. They latch onto a protein on the cancer cell’s surface and can do one of several things: block a growth signal from reaching the cell, flag the cell so the immune system attacks it, or, in an antibody-drug conjugate, ferry a potent chemotherapy payload directly to the cell and release it there. Mayo Clinic explains these mechanisms in its overview of monoclonal antibody drugs. Antibodies are large and are broken down slowly, so a single infusion can keep working for a long time, which is why infusion schedules are spaced out.

Other targeted medicines act on the tumor’s environment rather than the tumor itself. Angiogenesis inhibitors, for example, interfere with the growth of new blood vessels that a tumor needs to feed itself. These exist in both oral and infused forms.

None of these mechanisms is perfectly selective. The same signaling proteins often have jobs in healthy skin, gut lining, blood vessels and heart muscle, which explains why side effects cluster in those tissues even when the treatment is “targeted.” Understanding that helps make sense of the monitoring described later in this article.

Who is usually offered targeted therapy, and who is asked to wait

Targeted therapy is only useful when the target is present. That single fact determines most of who is offered it and who is not. Before prescribing, the team usually orders biomarker testing: laboratory analysis of tumor tissue from a biopsy or surgery, or sometimes of a blood sample, to look for the specific gene changes or proteins that a given medicine acts on.

The National Cancer Institute’s guidance on biomarker testing notes that results commonly take days to a few weeks to return, and that some tests require a fresh biopsy if stored tissue is insufficient. This is the most common reason a person is asked to wait: not because the team is undecided, but because the decision cannot responsibly be made without the result.

People are typically offered targeted therapy when:

• A validated biomarker is found that matches an approved or guideline-supported medicine for their cancer type and stage.
• Organ function, particularly liver, kidney and heart, is adequate for the specific medicine being considered.
• The treatment plan calls for it as a first-line option, after another treatment, or alongside surgery, radiation or chemotherapy.

People are more often asked to wait, or offered a different approach, when:

• Biomarker results are pending or inconclusive.
• They are still recovering from surgery and wound healing could be affected by medicines that interfere with blood vessel growth.
• Another treatment needs to be completed or washed out first.
• Pregnancy is possible or planned, since many of these medicines are not considered safe in pregnancy and contraception planning comes first.
• An uncontrolled medical condition, such as very high blood pressure or heart failure, needs stabilizing before a medicine that could worsen it is started.

A negative biomarker test is not a verdict on the seriousness of the cancer or on the person. It means a particular lock does not fit a particular key, and the team will look at other options. All of these are judgments for the treating oncologist, made with the full picture in view.

Targeted therapy tablets at home: what daily oral treatment really involves

The freedom of treatment at home is real, and so is the responsibility. When a medicine is swallowed, the person taking it becomes the one who administers it, records it and notices problems first.

The daily routine is usually simple in outline: take the medicine at roughly the same time each day, exactly as the label and the pharmacist describe. The details differ by medicine, and they matter. Some oral targeted medicines must be taken on an empty stomach because food changes how much is absorbed; others must be taken with food for the opposite reason. Some should be swallowed whole because crushing or opening them alters release. The Cleveland Clinic’s overview of targeted therapy stresses following the specific instructions provided rather than general assumptions.

Practical habits that oncology pharmacists commonly recommend include:

• Using a phone alarm or a simple diary to log each dose, so that any missed day can be reported accurately.
• Storing the medicine as the label directs, away from heat and moisture, and out of reach of children and pets.
• Washing hands after handling, and asking the pharmacist whether caregivers should use gloves.
• Keeping the original container so the name and lot are always available in an emergency.

Missed doses happen. The safe response is not to double up the next day but to follow the specific instruction the team gave for that medicine, which often depends on how many hours have passed. If no instruction was given, a call to the clinic or pharmacy line is the right move.

Adherence, the term for taking a medicine as prescribed over time, tends to erode quietly. Side effects, travel, a hospital admission for something unrelated, or simple fatigue can all interrupt a daily habit. Teams generally prefer to hear about difficulties early, because there are often ways to adjust the plan. What they cannot do is fix a problem no one has mentioned.

What happens on an infusion day, step by step

An infusion day has a rhythm that becomes familiar after the first visit. Knowing the sequence in advance takes some of the edge off.

Check-in and vital signs come first: temperature, blood pressure, pulse and often weight, since some medicines are calculated by body size. A nurse then draws blood, or accesses a port if one has been placed. A port is a small device under the skin of the chest connected to a large vein, used to make repeated infusions and blood draws easier; not everyone needs one, and the team decides.

There is usually a wait while the laboratory processes the sample. The medicine is generally not mixed by the pharmacy until the results confirm it is safe to proceed that day, which is why infusion visits often run longer than the drip itself. If a count or a chemistry value is off, the infusion may be delayed rather than given.

Many antibody infusions are preceded by premedication, typically an antihistamine and a fever reducer, sometimes a corticosteroid, to lower the chance of an infusion reaction. Mayo Clinic notes that reactions, which can include chills, fever, rash, itching, nausea or shortness of breath, are more likely during the first infusion, so the first dose is often run more slowly and with closer observation. Later infusions are frequently shorter when the first has been tolerated.

During the infusion, the nurse checks vital signs at intervals and asks how you feel. Speaking up about a flushed face, a tight throat or an itchy palm is not fussing; the pump can be paused and the reaction managed. Afterward there may be an observation period before discharge.

Bring what makes hours in a chair tolerable: layers, headphones, a book, a charger, snacks if permitted. Arrange a ride for the first visit, since premedication can cause drowsiness. Most centers provide a written schedule of upcoming infusion dates so the rest of life can be planned around them.

Injections under the skin and other less common routes

Not every non-oral targeted medicine requires a vein. Some monoclonal antibodies have been reformulated for subcutaneous injection, meaning delivery into the fatty layer just under the skin, usually of the thigh or abdomen. These are typically given by a nurse in a clinic, and the injection itself takes minutes rather than the hours an infusion can occupy, though observation time is still built in, especially for early doses.

The appeal is practical. There is no line to place, no pump to program and a shorter chair time. The medicine is the same molecule, so the mechanism, the spacing between doses and the monitoring plan remain the same as for the infused version. The team’s choice between the two forms depends on what is approved for a given cancer, what the person’s veins and preferences allow, and clinic logistics.

Injection-site reactions, such as redness, tenderness or a small firm area, are common and usually settle on their own. Nurses rotate sites to reduce this. Systemic reactions can still occur, so the same alertness to fever, chills or breathlessness applies.

A few targeted medicines follow more specialized routes for specific situations:

• Intravesical delivery, in which a medicine is instilled directly into the bladder through a catheter and held for a set time, is used for some bladder cancers.
• Intrathecal delivery into the fluid around the spinal cord is rare but used when disease involves the lining of the brain.
• Topical forms exist for a small number of skin-directed treatments.

These routes are chosen because they put the medicine where the disease is while limiting exposure elsewhere. They are always given by trained staff, never self-administered.

Whatever the route, the principle is the same one the National Cancer Institute sets out: match the delivery method to the medicine’s chemistry and the location of the cancer, and monitor accordingly. The route is a tool, not a ranking of how serious the treatment is.

Targeted therapy vs chemotherapy: how the routines compare

People often arrive at their first appointment carrying a mental picture of chemotherapy and assuming targeted therapy will look the same. Sometimes it does. Often the daily experience is quite different, and the two are frequently given together rather than as alternatives. The table below summarizes typical patterns; individual regimens vary, and the treating team’s plan takes precedence.

Feature	Targeted therapy (typical)	Traditional chemotherapy (typical)
What it acts on	Specific molecules or gene changes in cancer cells	Rapidly dividing cells, cancerous and healthy
Common route	Daily oral tablets or capsules; infusions or subcutaneous injections for antibodies	Mostly intravenous infusions; some oral forms
Usual rhythm	Continuous daily dosing, or infusions spaced by weeks	Cycles with infusion days followed by recovery weeks
Where treatment happens	Often largely at home for oral medicines	Mostly in an infusion unit
Side effect pattern	Skin, nails, gut, blood pressure, liver, heart or eyes, depending on the target	Low blood counts, nausea, hair loss, mouth sores, fatigue
Hair loss	Uncommon with many, though hair thinning or texture change can occur	Common with many regimens
Monitoring focus	Organ function specific to the medicine; scans for response	Blood counts before each cycle; scans for response
Requires a biomarker	Usually yes	Usually no

The National Cancer Institute’s overview of targeted therapy describes this distinction in mechanism, and the Cleveland Clinic notes that the side effect profile differs because healthy dividing cells are less broadly affected.

Two cautions belong here. First, “fewer of the classic chemotherapy side effects” is not the same as “few side effects.” Some targeted medicines produce rashes, diarrhea or blood pressure changes that are demanding in their own way. Second, many modern regimens layer the two approaches, so a person may have infusion days that include both an antibody and a chemotherapy drug, plus a tablet at home. Ask which elements of your plan are which; the answer shapes what to watch for.

How long does targeted therapy last? Cycles, breaks and open-ended treatment

The honest answer is that duration depends on the goal of treatment, and it is one of the first things to ask the team to spell out.

When targeted therapy is given alongside or after surgery to lower the chance of the cancer returning, the course often has a defined length set by the protocol the team is following. When it is given for cancer that has spread, the National Cancer Institute notes that treatment is often continued for as long as it is working and the side effects are manageable. That can mean many months or years, and the phrase “open-ended” can be unsettling until it is understood as a sign of benefit rather than of failure to finish.

Cycles help structure either approach. For an infused antibody, a cycle might be one infusion followed by a fixed interval before the next. For a daily tablet, a cycle might mean a stretch of consecutive treatment days followed by a planned pause, or simply a set number of weeks after which blood tests and a review are scheduled. The pause, where one exists, is part of the design: it gives skin, gut lining and blood counts time to recover.

Treatment can also be interrupted deliberately. Teams may pause a medicine to let a side effect settle, before a surgical procedure because some medicines affect wound healing, or during an unrelated illness. These holds are decided by the prescriber, who weighs the risk of a gap against the risk of continuing. Stopping or restarting on one’s own is not advised.

Response is judged mainly by scans and, for some cancers, by blood markers, repeated at intervals the team sets. A cycle count or a scan date on the calendar can become a reference point for the whole household. Knowing when the next assessment is, and what the team will be looking for, tends to make the stretch between visits easier to carry.

What the first days and weeks on targeted therapy usually look like

The opening weeks are a period of calibration for both the body and the care plan. Most people describe them as busier than expected, not because the treatment itself takes long, but because monitoring is closest at the start.

For oral medicines, the first days are often uneventful. Small-molecule drugs need time to reach a steady level in the blood, and many side effects, such as the acne-like rash associated with medicines that block the epidermal growth factor receptor (a protein on skin and tumor cells), tend to emerge over the first several weeks rather than the first day. Diarrhea, a common effect of several kinase inhibitors, can start earlier. Teams often schedule blood tests more frequently in the first cycle to check liver enzymes and blood counts, then space them out once the pattern is clear.

For infusions, the first visit is usually the longest, for the reasons described earlier: slower rate, premedication, observation. Some people feel washed out or feverish that evening; others feel nothing at all. A nurse call the next day is common practice in many units.

Across both routes, the early weeks typically include:

• A follow-up appointment or phone review to compare how you feel against what the team expected.
• Instruction on managing predictable effects: skin moisturizing, sun protection, mouth care, hydration.
• Baseline measurements that later checks will be compared with, such as a heart ultrasound for medicines that can affect heart muscle, or blood pressure readings for medicines that affect blood vessels.

Fatigue is the most universal early companion and the hardest to quantify. It usually responds better to gentle, regular activity than to complete rest, though the team can advise on what is safe with any particular blood count or heart finding.

Above all, the first weeks are when reporting matters most. A side effect noticed early is usually a side effect the team can manage while keeping treatment on track.

How is targeted therapy given between visits? The monitoring routine explained

The infusion chair and the pill bottle are the visible parts of treatment. The routine between visits is where safety lives. It exists because targeted medicines act on proteins that healthy tissues also use, and the effects on those tissues are often silent until a test reveals them.

Blood tests are the backbone. Depending on the medicine, these may track blood counts, liver enzymes, kidney function, electrolytes such as potassium and magnesium, thyroid hormone levels, or blood sugar. The frequency is highest early and typically lengthens as results stabilize. Many people have blood drawn at a local laboratory a day or two before a clinic visit so results are ready for the appointment.

Other checks are medicine-specific:

• An echocardiogram, an ultrasound of the heart, is repeated at intervals for medicines that can weaken heart muscle.
• An electrocardiogram, a tracing of the heart’s electrical rhythm, is used for medicines that can prolong a particular interval in that rhythm.
• Blood pressure is monitored at home for medicines that affect blood vessels; the team will say what readings should prompt a call.
• Eye examinations are scheduled for a small number of medicines known to affect the retina or cornea.
• Skin and nail reviews catch problems before they become infected or disabling.

Imaging, usually a computed tomography scan or, for some cancers, a magnetic resonance or positron emission scan, is repeated at intervals the team sets to judge whether the cancer is responding. These are the appointments most people find most tense, and it is reasonable to ask how and when results will be communicated.

Between all of this, the practical thread is the clinic’s contact line. Most cancer centers run a nurse-staffed line for questions and symptom reports, often with an after-hours number. Keeping it saved in a phone and knowing which symptoms warrant a same-day call, rather than a note for the next visit, is part of how targeted therapy is safely given at home. A short symptom diary, updated daily, turns vague recollection into something the team can act on.

Targeted therapy side effects and how they are watched

The phrase “targeted” sets an expectation of precision that the body does not always honor. The proteins these medicines block are shared, in varying degrees, with normal cells, and side effects follow those shared pathways in fairly predictable ways. The National Cancer Institute lists the common categories.

Skin is affected by many oral kinase inhibitors: dryness, an acne-like rash, changes to nails and the skin around them, and hand-foot skin reaction, a tender redness or thickening on palms and soles. Diarrhea, mouth sores and appetite changes reflect effects on the gut lining. Raised blood pressure, slower wound healing and a tendency to bleed or bruise are associated with medicines that interfere with blood vessel growth. Some medicines can affect liver enzymes, thyroid function, blood sugar or heart muscle, and a smaller number can cause inflammation in the lungs that presents as a new dry cough or breathlessness.

Antibody infusions carry the additional possibility of infusion reactions, discussed earlier, and antibody-drug conjugates can produce effects related to the chemotherapy payload they carry, including low blood counts.

What matters for daily life is how these are handled:

• Many effects are graded on a standard scale, and the team uses that grade to decide whether to continue, pause or adjust. Those decisions belong to the prescriber.
• Preventive measures, such as moisturizers, sun protection, mouth rinses and early anti-diarrheal guidance, are usually explained at the start and are worth asking about if they were not.
• Low blood counts raise infection risk. The National Cancer Institute’s guidance on infection during cancer treatment identifies a temperature of 100.4°F (38°C) or higher as a reason to call immediately.

A recurring theme in oncology nursing is that side effects reported early tend to be managed with smaller interventions than those reported late. Stopping a medicine independently to escape a side effect removes both the effect and the benefit, and it deprives the team of the chance to find a middle path. Report first; adjust together.

Food, other medicines and supplements: interactions worth asking about

Oral targeted medicines share the body’s chemistry with everything else that is swallowed. Many small-molecule kinase inhibitors are broken down by a liver enzyme system called cytochrome P450, and anything that speeds up or slows down those enzymes can push drug levels too low to work or too high to tolerate. The team and pharmacist will review the full list of medicines at the start, but the list changes over time, and that is where problems arise.

Items that commonly come up in oncology pharmacy reviews include:

• Grapefruit and grapefruit juice, which inhibit a key enzyme and can raise levels of several oral cancer medicines; Seville oranges and pomelo act similarly.
• St. John’s wort, a herbal supplement that induces the same enzyme system and can lower levels of many medicines; the NIH Office of Dietary Supplements documents its interactions.
• Acid-reducing medicines, including proton pump inhibitors and H2 blockers, which raise stomach pH and reduce absorption of some kinase inhibitors that need an acidic environment to dissolve.
• Certain antibiotics, antifungals and anti-seizure medicines, which are well-known enzyme inhibitors or inducers.
• Blood thinners, whose effect can be amplified by medicines that affect platelets or blood vessel integrity.

Supplements deserve particular attention because they are often started without a prescriber’s knowledge. High-dose antioxidants, turmeric extracts, green tea concentrates and others have been studied for interactions with cancer medicines, and the evidence is mixed and medicine-specific. The neutral position most guidelines take is not that supplements are forbidden, but that each one should be disclosed and checked.

Food timing is its own category. If a medicine is labeled for an empty stomach, the pharmacist can explain what that means in hours before and after eating. For infused antibodies, dietary interactions are far less of an issue, since the medicine bypasses the gut entirely.

A simple habit prevents most trouble: before starting anything new, including an over-the-counter cold remedy or a vitamin, ask the oncology pharmacist. A two-minute call is a small price for keeping a treatment plan on track.

What people often get wrong about how targeted therapy is given

Misunderstandings about delivery are common, and some of them lead to real harm. Here are the ones oncology teams hear most often, with the evidence-based correction.

“A tablet means it is a milder treatment.” The route reflects chemistry, not potency. Oral kinase inhibitors are potent medicines with real toxicity, and the fact that they are taken at home makes vigilance more important, not less. Cleveland Clinic’s guidance emphasizes that oral targeted medicines require the same care as any cancer treatment.

“Targeted means no side effects.” As the earlier sections describe, shared signaling pathways mean skin, gut, blood vessels and organs can all be affected. The pattern differs from chemotherapy; the burden is not necessarily lighter.

“If I feel fine, missing a day here and there does not matter.” For daily small molecules, steady blood levels are the point. Gaps let the blocked signal resume. Missed doses should be reported, not hidden, and never compensated for by taking extra.

“If I feel terrible, I should stop until I see the doctor.” Stopping is sometimes exactly what the team will advise, but that judgment should be theirs, made quickly over the phone. Unilateral stops and restarts complicate both safety and interpretation of scans.

“Targeted therapy replaces chemotherapy.” Often the two are combined, and many plans include hormone therapy, radiation or surgery as well. Knowing which element is which helps you know what to watch for.

“Targeted therapy and immunotherapy are the same thing.” They are distinct categories. Immunotherapy works by activating the immune system; most targeted medicines act directly on cancer cell machinery. Some antibodies blur the line, which is a good question for the team.

“Natural supplements are safe alongside.” Several common supplements alter drug metabolism, as the previous section explains. Disclosure is the safe default.

“An infusion is stronger than an injection or a tablet.” Subcutaneous and intravenous forms of the same antibody deliver the same molecule. Neither is a lesser version.

Questions to ask your care team before and during targeted therapy

A first oncology consultation moves fast, and the questions that matter most often surface on the drive home. Writing them down in advance, and bringing someone to take notes, changes the quality of the conversation. The following are questions people who have been through this commonly wish they had asked earlier. None has a universal answer; all belong to your team.

About the medicine and its route:

• Which biomarker result led to this recommendation, and what does it mean for how the medicine works?
• Will this be taken at home, given by infusion, by injection, or a combination? Why this route for me?
• Is this being given alone or alongside chemotherapy, hormone therapy or another treatment?

About the schedule:

• What does one cycle look like, and how many are planned before the first assessment?
• Is there a defined end point, or will treatment continue as long as it is working?
• What should I do if a dose is missed, and how many hours late is too late?

About monitoring:

• Which blood tests, heart checks or eye checks will be repeated, how often, and where can they be done?
• When is the first scan, and how will results be shared with me?
• What is the number to call for symptoms, and which symptoms should prompt a call the same day versus an emergency visit?

About daily life:

• Should this be taken with or without food, and are there foods or drinks to avoid?
• Which of my current medicines and supplements need review?
• Can I work, drive, travel, exercise, or have dental work during treatment?
• Is contraception needed, and for how long after treatment ends?

About what comes next:

• What would lead you to pause or change this medicine?
• If this stops working, what are the likely next options?

These are not challenges to the team’s expertise. Good clinicians welcome them, because a person who understands the plan is a person who follows it safely and reports problems early.

When to call your doctor: red-flag signs during targeted therapy

Most days on targeted therapy are ordinary. The routine between visits is designed so that when something is not ordinary, it is caught fast. Knowing the threshold for a same-day call, and for an emergency visit, is part of being safely on treatment at home. The list below reflects guidance from the National Cancer Institute on infection during cancer treatment and general oncology safety practice; your team may give you a more specific list for your medicine, and theirs takes precedence.

Call the oncology team the same day, or the after-hours line, for:

• A temperature of 100.4°F (38°C) or higher, or chills and shaking even without a measured fever, since some medicines lower the white blood cells that fight infection.
• Diarrhea that is significantly more frequent than your usual, especially with dizziness or reduced urination, which signal dehydration.
• Mouth sores or nausea severe enough to prevent drinking fluids.
• A new or worsening rash, particularly with blistering, peeling or involvement of the eyes or mouth.
• Blood pressure readings above the threshold your team gave you, or a persistent severe headache.
• Yellowing of the skin or eyes, dark urine, or pale stools, which can indicate liver stress.
• Unexplained bruising, nosebleeds that do not stop, or blood in urine or stool.

Seek emergency care immediately, and tell staff which cancer medicine you take, for:

• Chest pain, pressure or a racing, irregular heartbeat.
• Sudden breathlessness, a new dry cough that worsens quickly, or lips turning blue.
• Swelling of the face, tongue or throat, or difficulty swallowing or breathing during or after an infusion or injection.
• Sudden weakness on one side, slurred speech, confusion or a seizure.
• Pain, warmth and swelling in one calf, which can indicate a blood clot.
• Sudden loss of vision or severe eye pain.

When in doubt, call. Oncology nurses would far rather field a call that turns out to be nothing than hear about a fever the next morning. Every decision about pausing, adjusting or continuing treatment rests with the treating team, and they can only make it if they know what is happening.

Frequently asked questions

How is targeted therapy given most often, by tablet or by infusion?

Both are common, and which one applies depends on the medicine rather than on how serious the cancer is. Small-molecule targeted drugs, including most kinase inhibitors, are typically taken as daily tablets or capsules at home. Monoclonal antibodies are given by infusion into a vein or, for some formulations, by injection under the skin, because they are proteins that would be broken down if swallowed. Some plans combine both.

Can I take targeted therapy tablets at home without visiting the clinic?

The tablets themselves are taken at home, but treatment still involves regular clinic contact. Blood tests, and for some medicines heart or eye checks, are scheduled at intervals the team sets, usually closer together in the first weeks. Scans are repeated to assess response. Most centers also run a nurse line for symptom reports between visits. Taking the medicine at home shifts responsibility for daily dosing and early reporting onto you and your household.

What is the difference between targeted therapy vs chemotherapy in how they are given?

Chemotherapy is mostly infused in cycles with recovery weeks between, while many targeted medicines are taken daily at home or infused at spaced intervals. Their side effect patterns also differ: chemotherapy tends to lower blood counts and cause hair loss, whereas targeted medicines more often affect skin, gut, blood pressure or specific organs. The two are frequently given together, so ask which parts of your plan are which.

How long does targeted therapy last?

It depends on the goal. When given around surgery to reduce the chance of recurrence, the course usually has a defined length set by the protocol. When given for cancer that has spread, the National Cancer Institute notes treatment often continues as long as it is working and side effects are manageable, which may be months or years. Your team can tell you which applies and when the first assessment scan is planned.

What are the most common targeted therapy side effects to expect in the first weeks?

Fatigue, skin changes such as dryness or an acne-like rash, diarrhea, mouth soreness and, for infused antibodies, a possible reaction during the first infusion are among the most frequently reported early effects. Some medicines can also raise blood pressure or affect liver tests, which is why blood work is closest together at the start. Report anything new early; small adjustments made promptly are usually easier than large ones made late.

What happens if I miss a dose of my targeted therapy tablet?

Follow the specific missed-dose instruction your team or pharmacist gave for that medicine, since the right response often depends on how many hours have passed. Do not take extra to make up for it. If you were not given an instruction, call the clinic or pharmacy line rather than guessing. Record the missed dose in your diary so the team has an accurate picture at your next review.

Why is the first infusion longer than the later ones?

Infusion reactions to monoclonal antibodies are most likely during the first dose, so teams typically run it more slowly, give premedication such as an antihistamine and a fever reducer, and observe you closely afterward. Once the first infusion has been tolerated, later ones can often be given at a faster rate with a shorter visit. The wait for blood results before the pharmacy prepares the medicine also adds time on every visit.

Do I need a port for targeted therapy infusions?

Not necessarily. A port is a small device placed under the skin of the chest to give repeated access to a large vein. Whether one is recommended depends on how many infusions are planned, whether chemotherapy is being given alongside, the condition of your arm veins and your preference. Some antibodies are available as under-the-skin injections, which avoid the need for a vein altogether. The decision sits with your treating team.

Can I eat grapefruit or take supplements while on oral targeted therapy?

Grapefruit and related citrus can raise blood levels of several oral cancer medicines by blocking a liver enzyme, and St. John’s wort can lower them by speeding the same enzyme up. Acid-reducing medicines can reduce absorption of some kinase inhibitors. Because the effect is medicine-specific, the safe approach is to disclose every supplement, herbal product and over-the-counter medicine to your oncology pharmacist before starting it.

When should I go to the emergency department rather than call the clinic?

Go immediately for chest pain, sudden breathlessness, swelling of the face or throat, one-sided weakness or slurred speech, confusion, a seizure, sudden vision loss, or a painful swollen calf. Call the oncology team the same day for a temperature of 100.4°F (38°C) or higher, severe diarrhea, inability to keep fluids down, a blistering rash, yellowed skin or unusual bleeding. Always tell emergency staff which cancer medicine you take.

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.